Stockscreener 앱 받기
0.3337
4.03%
-0.014
전일 마감가:
$0.3477
열려 있는:
$0.35
하루 거래량:
153.13K
Relative Volume:
0.46
시가총액:
$15.10M
수익:
$106.79M
순이익/손실:
$-8.73M
주가수익비율:
-1.6685
EPS:
-0.2
순현금흐름:
$10.81M
1주 성능:
-12.76%
1개월 성능:
-16.64%
6개월 성능:
-86.04%
1년 성능:
-91.33%
1일 변동 폭
$0.3323
$0.35
1주일 범위
$0.3321
$0.3922
52주 변동 폭
$0.3321
$4.08
Harvard Bioscience Inc Stock (HBIO) Company Profile
명칭
Harvard Bioscience Inc
전화
(508) 893-8999
주소
84 OCTOBER HILL RD, HOLLISTON, MA
HBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.3376 | 15.10M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
534.76 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
167.69 | 48.46B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
97.93 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
241.08 | 35.24B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.36 | 16.39B | 3.90B | 392.30M | 288.10M | 1.95 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 개시 | Northland Capital | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-01-24 | 재확인 | Janney | Buy |
| 2018-01-23 | 재확인 | The Benchmark Company | Buy |
| 2016-11-17 | 개시 | Singular Research | Buy |
| 2015-07-28 | 개시 | The Benchmark Company | Buy |
모두보기
Harvard Bioscience Inc 주식(HBIO)의 최신 뉴스
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)? - simplywall.st
Harvard Bioscience (NASDAQ:HBIO) Coverage Initiated at StockNews.com - American Banking and Market News
Press Release Distribution & PR Platform - ACCESS Newswire
Harvard Bioscience Inc [HBIO] Shares Rise 1.22 % on Wednesday - knoxdaily.com
Did Harvard Bioscience Inc (HBIO) perform well in the last session? - uspostnews.com
Market Watch: Harvard Bioscience Inc (HBIO)’s Noteworthy Gain, Closing at 0.40 - DWinneX
Harvard Bioscience’s Bertrand Loy to Step Down - TipRanks
Benchmark reiterates Harvard Bioscience stock with $4.50 target - Investing.com
Benchmark reiterates Harvard Bioscience stock with $4.50 target By Investing.com - Investing.com India
Harvard Bioscience’s (HBIO) Sector Weight Rating Reiterated at KeyCorp - Defense World
Harvard Bioscience (HBIO) Announces CFO Transition - GuruFocus
Harvard Bioscience Announces CFO Transition | HBIO Stock News - GuruFocus
Harvard Bioscience (HBIO) Sees CFO Transition with Interim Appoi - GuruFocus
Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop - simplywall.st
Harvard Bioscience Appoints Mark Frost as Interim CFO - citybiz
Harvard Bioscience appoints interim CFO amid market challenges By Investing.com - Investing.com Canada
Harvard Bioscience CFO Jennifer Cote Resigns - marketscreener.com
Harvard Bioscience CFO Resignation and Interim Appointment - TipRanks
Harvard Bioscience appoints interim CFO amid market challenges - Investing.com
Harvard Bioscience Announces CFO Transition - The Manila Times
KeyBanc cuts Harvard Bioscience stock rating on financing risk By Investing.com - Investing.com Canada
Estimating The Fair Value Of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Yahoo Finance
KeyBanc Downgrades Harvard Bioscience to Sector Weight From Overweight, Removes $3 Price Target - marketscreener.com
KeyBanc cuts Harvard Bioscience stock rating on financing risk - Investing.com
Harvard Bioscience Slides As Insider Purchases Lose Another US$76k - simplywall.st
Harvard Bioscience (NASDAQ:HBIO) Price Target Cut to $4.50 by Analysts at Benchmark - Defense World
Harvard Bioscience at KeyBanc Forum: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com South Africa
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Harvard Bioscience Reports 2024 Financial Results - TipRanks
Harvard Bioscience Navigates Growth Amid Challenges - TipRanks
Harvard Bioscience secures waiver for credit covenant By Investing.com - Investing.com Australia
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 - GlobeNewswire
Harvard Bioscience CEO to Host Fireside Chats at Roth and KeyBanc Healthcare Forums - StockTitan
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Earnings call transcript: Harvard Bioscience Q4 2024 beats expectations but faces market challenges - Investing.com
Harvard Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harvard Bioscience slumps after weak revenue forecast - TradingView
HARVARD BIOSCIENCE Earnings Results: $HBIO Reports Quarterly Earnings - Nasdaq
Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year - TipRanks
Harvard Bioscience earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Harvard Bioscience Achieves Profit Turnaround Despite Revenue Challenges in Latest Quarter - StockTitan
Harvard Bioscience Inc (HBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Harvard Bioscience Inc 주식 (HBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Green James W | Chief Executive Officer |
Jun 06 '24 |
Buy |
3.07 |
20,000 |
61,400 |
3,101,091 |
0.67%
0.53%
자본화:
|
볼륨(24시간):